The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / TRK / ALK / RET / EGFR Inhibitors, Clinical Trial Outcomes, Mechanisms of Resistance, and Safety Profiles

0 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login